These 10 Stocks are Winning Big

Ten stocks rose on Monday, outperforming a mixed performance among Wall Street’s major indices, as investors digested a flurry of catalysts, including corporate earnings and the agreed-upon trade deal between the US and the European Union.

Among Wall Street’s main indices, only the Nasdaq and S&P 500 finished in the green, up 0.33 percent and 0.02 percent, respectively. The Dow Jones was down by 0.14 percent.

In this article, we highlight the names of the 10 best-performing stocks and detail the reasons behind their gains.

To compile the list, we focused on stocks with more than $300 million in capitalization and 5 million shares in trading volume.

A man in a black suit holding a tablet looks at stock market data on a monitor. Photo by Tima Miroshnichenko on Pexels

10. Patterson-UTI Energy, Inc. (NASDAQ:PTEN)

Patterson-UTI bounced back by 5.41 percent on Monday to close at $6.24 apiece as investors loaded up positions following a two-day drop dragged by dismal earnings performance.

During the period, Patterson-UTI Energy, Inc. (NASDAQ:PTEN) said it swung to a net loss attributable to shareholders of $49 million from an $11 million net income in the same period last year, as revenues dropped by 7 percent to $1.2 billion from $1.3 billion year-on-year.

The performance was largely dampened by increasing oil market volatility during the quarter, driven by evolving trade policies, among others.

For the six-month figure, Patterson-UTI Energy, Inc. (NASDAQ:PTEN) also reversed a $62-million net income attributable to shareholders last year after booking a $48-million net loss in the first half of the year. Revenues were lower by 10.7 percent to $2.5 billion from $2.8 billion year-on-year.

Patterson-UTI Energy, Inc. (NASDAQ:PTEN) also declared a $0.08 dividend to shareholders as of September 2, payable on September 15.

9. Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Esperion Therapeutics extended its winning streak to a fifth consecutive day on Monday, adding 5.3 percent to close at $1.59 apiece as investors gobbled up shares ahead of its earnings release amid reports that it was set to be acquired by a Japan-based pharmaceutical company.

According to a post by @rumourbuyouts on X, pharmaceutical firm Otsuka is said to be in talks to fully acquire Esperion Therapeutics, Inc. (NASDAQ:ESPR) in a deal that could potentially be valued $900 million. The post added that the two companies are set to meet in August to discuss a deal.

Based on the social media handle, @rumourbuyouts is currently based in Japan and only has 177 followers.

Meanwhile, Esperion Therapeutics, Inc. (NASDAQ:ESPR) said that it is scheduled to release the results of its second quarter earnings performance before market open on August 5, Tuesday.